Back to Journals » Journal of Blood Medicine » Volume 1

Emerging antiplatelet agents, differential pharmacology, and clinical utility

Authors Das, Oliphant CS, Beach E, Thapa R

Published 31 May 2010 Volume 2010:1 Pages 79—91


Review by Single-blind

Peer reviewer comments 4

Pranab Das1, Carrie S Oliphant2, Elizabeth Beach3, Rashmi Thapa4

1Assistant Professor, Division of Cardiology, Department of Internal Medicine, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA; 2Cardiology Clinical Pharmacy Specialist, Department of Pharmacy, Methodist University Hospital, and Assistant Professor University of Tennessee College of Pharmacy, Memphis, Tennessee, USA; 3PGY-1 Pharmacy Practice Resident, Department of Pharmacy, Methodist University Hospital, Memphis, Tennessee, USA; 4Resident, Department of Internal Medicine, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA

Abstract: The aspirin–clopidogrel combination is the current gold standard antiplatelet regimen following percutaneous coronary intervention and for the treatment of acute coronary syndrome. Despite the clinical benefit of this combination, patients continue to have vascular events. Another purinergic (P2Y12) receptor antagonist, prasugrel, became available last year. Although prasugrel is superior to clopidogrel in reducing clinical endpoints, a higher bleeding rate has been identified particularly in high-risk patients. Ticagrelor, a reversible P2Y12 receptor antagonist currently being evaluated for approval, is also more potent than clopidogrel but has a similar bleeding risk. Two additional P2Y12 antagonists are being investigated that will be available as an intravenous formulation. Apart from the P2Y12 receptor antagonists, multiple other agents are being developed with unique mechanisms of platelet inhibition. These agents are being studied as an alternative to or in combination with clopidogrel. The antiplatelet agents currently under development include: thrombin receptor antagonists, phosphodiesterase inhibitors, a thromboxane–prostaglandin receptor antagonist, a serotonin receptor blocker, a platelet adhesion antagonist, nitric oxide-releasing aspirin, a glycoprotein VI antagonist, and a cyclooxygenase inhibitor. The purpose of this review is to describe the efficacy and safety profiles of the emerging antiplatelet agents and their role in the treatment of atherosclerotic cardiovascular diseases.
Keywords: antiplatelet agents, safety, efficacy, clinical pharmacology, clinical trials

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]